Answers are grounded in this paper and cite their sources.
To determine whether naringenin ameliorates PCOS-associated miscarriage by targeting C/EBPβ-dependent decidual macrophage pyroptosis. Methods: DHEA-induced PCOS mice and an in vitro macrophage pyroptosis model were used. Transcriptomic profiling, PELSA-based target identification, molecular docking, molecular dynamics simulations, ChIP-qPCR, and gain-/loss-of-function experiments were performed. Results: Naringenin reduced embryo resorption and restored decidual homeostasis in PCOS mice. Transcriptomics identified macrophage pyroptosis via NLRP3/AIM2–caspase-1–GSDMD activation as a key pathological feature of PCOS decidua, which naringenin attenuated in vivo and in vitro. PELSA combined with structural validation identified C/EBPβ as a molecular target of naringenin. Pharmacological C/EBPβ inhibition attenuated pyroptosis, whereas C/EBPβ overexpression diminished naringenin's protection. Mechanistically, naringenin reduced C/EBPβ occupancy at Aim2, IL18, and IL1β promoters, suppressing inflammasome transcriptional activation. Naringenin ameliorates PCOS-associated miscarriage by targeting C/EBPβ, thereby suppressing inflammasome activation and decidual macrophage pyroptosis.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: